Evidence map›Paper›PMID 35568439›Full record

ArticleLupus science & medicine2022

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study.

Aurelien Schlencker, Laurent Messer, Marc Ardizzone, Gilles Blaison, Olivier Hinschberger, Etienne Dahan, Christelle Sordet, Julia Walther, Anne Dory, Maria Gonzalez and 7 more

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Aurelien SchlenckerService de Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
Laurent MesserService de Rhumatologie, Hôpitaux Civils de Colmar, Colmar, France.
Marc ArdizzoneService de Rhumatologie, GHR Mulhouse Sud-Alsace, Mulhouse, France.
Gilles BlaisonService de médecine interne, Centre de compétence Maladies auto-immunes rares, Hôpitaux Civils de Colmar, Colmar, France.
Olivier HinschbergerService de médecine interne, Centre de compétence Maladies auto-immunes rares, Hôpitaux Civils de Colmar, Colmar, France.
Etienne DahanService de Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
Christelle SordetService de Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
Julia WaltherService de pharmacie stérilisation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Anne DoryService de pharmacie stérilisation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Maria GonzalezService de Pathologie Professionnelle et de Médecine du Travail, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Stéphanie KleinlogelService de Pathologie Professionnelle et de Médecine du Travail, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Aurélia Bramont-NachmanService de Pathologie Professionnelle et de Médecine du Travail, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Lionel BarrandLaboratoire Barrand, Strasbourg, France.
Isabelle Payen-RevolMédiation Conseil Santé, Paris, France.
Jean SibiliaService de Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
Thierry MartinCentre National de Références des Maladies Auto-immunes Rares (CRMR RESO), Strasbourg, France.
Laurent ArnaudService de Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France laurent.arnaud@chru-strasbourg.fr.ORCID 0000-0002-8077-8394
Hôpitaux Universitaires de Strasbourg · FRHopitaux Civils de Colmar · FRGroupe Hospitalier de la Région de Mulhouse et Sud Alsace · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAmong the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirmed SLE.

methodsWe conducted a cross-sectional study of patients with SLE, healthcare providers and other representative stakeholders. Focus groups were conducted, and based on the collected data the most impactful disruption points in SLE patient pathways were identified. A novel framework to improve individual patient pathways in SLE was developed, discussed and validated during a consensus meeting with representative stakeholders.

resultsSix thematic clusters regarding disruption in optimal patient pathways in SLE were identified: appropriate and timely referral strategy for SLE diagnosis; the need for a dedicated consultation during which the diagnosis of SLE would be announced, and following which clarifications and psychological support offered; individualised patient pathways with coordinated care based on organ involvement, disease severity and patient preference; improved therapeutic patient education; prevention of complications such as infections, osteoporosis and cancer; and additional patient support. During the consensus meeting, the broader panel of stakeholders achieved consensus on these attributes and a framework for optimising SLE patient pathways was developed.

conclusionsWe have identified significant disruption points and developed a novel conceptual framework to improve individual patient pathways in SLE. These data may be of valuable interest to patients with SLE, their physicians, health organisations as well as policy makers.

Indexed as

Lupus Erythematosus, SystemicCross-Sectional StudiesFocus GroupsHumansSeverity of Illness Indexautoimmune diseasespatient care teampsychologyqualitative researchsystemic lupus erythematosus

Identifiers

PMID35568439
PMCPMC9109107
OpenAlexW4280572127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.